NCT00098163View on ClinicalTrials.gov

Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 2009

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC-HIV vCP1521

One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.

BIOLOGICAL

ALVAC HIV-1 vCP1521

One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.

Trial Locations (1)

Unknown

Makerere University- JHU Research Collaboration {MUJHU CARE LTD} CRS, Kampala

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00098163 - Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers | Biotech Hunter | Biotech Hunter